Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker

The widespread use of prostate‐specific antigen (PSA) screening has had a tremendous impact on all aspects of the management of prostate carcinoma. Although PSA‐based screening has resulted in a stage migration to more organ‐confined tumors at the time of diagnosis, and has been temporally associated with a decrease in prostate carcinoma mortality, PSA screening is imperfect. A recent analysis of results from the Prostate Cancer Prevention Trial (PCPT) has provided insight into the positive predictive value of PSA in the so‐called “normal” range.

[1]  W. Catalona,et al.  Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. , 1999, The Journal of urology.

[2]  C. Brendler,et al.  Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of <4.0 ng/mL , 2004, BJU international.

[3]  François G. Meyer,et al.  Dietary Fat and Prostate Cancer Progression and Survival , 1999, European Urology.

[4]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[5]  J. Thomas,et al.  Diet, micronutrients, and the prostate gland. , 2009, Nutrition reviews.

[6]  R. Vessella,et al.  The value of serum prostate specific antigen determinations before and after radical prostatectomy. , 1989, The Journal of urology.

[7]  U. Norming,et al.  Prostate-specific antigen (PSA), PSA density and age-adjusted PSA reference values in screening for prostate cancer--a study of a randomly selected population of 2,400 men. , 1998, Scandinavian journal of urology and nephrology.

[8]  K. Cummings,et al.  National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. , 1998, Urology.

[9]  I. Thompson,et al.  Expectant management of localized prostatic cancer , 1991, Cancer.

[10]  W. Catalona,et al.  Clinical use of prostate specific antigen in patients with prostate cancer. , 1989, The Journal of urology.

[11]  E. Rimm,et al.  Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. , 1998, Journal of the National Cancer Institute.

[12]  R. G. Wendel,et al.  Complications of punch biopsy of the prostate gland. , 1967, The Journal of urology.

[13]  I. Thompson,et al.  Adenocarcinoma of the prostate: results of routine urological screening. , 1984, The Journal of urology.

[14]  P. Walsh.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. , 2003, The Journal of urology.

[15]  P. Carpenter,et al.  A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. , 2001, Cancer research.

[16]  W. A. Soanes,et al.  Tissue- and species-specific antigens of normal human prostatic tissue. , 1970, Journal of immunology.

[17]  D. Gillatt,et al.  High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response. , 1989, Urology.

[18]  O. Cussenot,et al.  Familial prostate cancer cases before and after radical prostatectomy do not show any aggressiveness compared with sporadic cases. , 2003, Urology.

[19]  E. Crawford,et al.  Prostate Cancer Awareness Week, 1992: a summary of key findings. , 1993, Clinical and investigative medicine. Medecine clinique et experimentale.

[20]  G. Chodak,et al.  Early detection of prostate cancer by routine screening. , 1984, JAMA.

[21]  V. Reuter,et al.  Clinical significance of repeat sextant biopsies in prostate cancer patients. , 1997, Urology.

[22]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[23]  T. S. Li,et al.  Isolation and characterization of two specific antigens of human seminal plasma. , 1973, Fertility and sterility.

[24]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[25]  T. Rebbeck,et al.  More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. , 2000, Journal of the National Cancer Institute.

[26]  H. Klocker,et al.  Characteristics of prostate cancers detected at low PSA levels , 2004, The Prostate.

[27]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[28]  M. Benson,et al.  The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. , 1992, The Journal of urology.

[29]  J. Stanford,et al.  The association of fatty acids with prostate cancer risk , 2001, The Prostate.

[30]  W. Catalona,et al.  Screening for prostate cancer in high risk populations. , 2002, The Journal of urology.

[31]  H. D. de Koning,et al.  Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). , 2004, Urology.

[32]  M. Soloway,et al.  The procedure of transrectal ultrasound guided biopsy of the prostate: a survey of patient preparation and biopsy technique. , 2002, The Journal of urology.

[33]  S. Reis,et al.  Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. , 2001, Journal of the National Cancer Institute.

[34]  M. Luján,et al.  Prostate cancer detection is also relevant in low prostate specific antigen ranges. , 2004, European urology.

[35]  P. Esposti,et al.  Complications of transrectal aspiration biopsy of the prostate. , 1975, Scandinavian journal of urology and nephrology.

[36]  W. Ellis,et al.  Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. , 1994, The Journal of urology.

[37]  P. Schellhammer,et al.  Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. , 2002, Clinical chemistry.

[38]  T. Stamey,et al.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. , 1988, The New England journal of medicine.

[39]  C G Chute,et al.  Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. , 1995, JAMA.

[40]  R. Kane,et al.  The results of a five‐year early prostate cancer detection intervention , 1996, Cancer.

[41]  M. Terris,et al.  Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. , 1989, The Journal of urology.

[42]  T. Stamey,et al.  Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. , 2003, The Journal of urology.

[43]  K. Mitsumori,et al.  Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/mL equivalent to that in men with 4.1 to 10.0 ng/mL in a Japanese population. , 2004, Urology.

[44]  M. Barak,et al.  Evaluation of prostate-specific antigen as a marker for adenocarcinoma of the prostate. , 1989, The Journal of laboratory and clinical medicine.

[45]  H. Olsson,et al.  Clinical Course of Early Onset Prostate Cancer with Special Reference to Family History as a Prognostic Factor , 1998, European Urology.

[46]  D. Siders,et al.  Use of transrectal ultrasound in diagnosis, guided biopsy, staging, and screening of prostate cancer. , 1989, Urology.

[47]  H. Lilja.  A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. , 1985, The Journal of clinical investigation.

[48]  E. Feuer,et al.  Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. , 1999, Journal of the National Cancer Institute.

[49]  G. Sensabaugh,et al.  Isolation and characterization of a semen-specific protein from human seminal plasma: a potential new marker for semen identification. , 1978, Journal of forensic sciences.

[50]  D. Ornstein,et al.  Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. , 1997, The Journal of urology.

[51]  A. Gutman,et al.  Theory and Application of the Serum “acid” Phosphatase Determination in Metastasizing Prostatic Carcinoma; Early Effects Of Castration , 1942 .

[52]  W. Ellis,et al.  The inability of prostate specific antigen index to enhance the predictive the value of prostate specific antigen in the diagnosis of prostatic carcinoma. , 1993, The Journal of urology.

[53]  A S Whittemore,et al.  Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer , 1993, Cancer.

[54]  O John Semmes,et al.  Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  K. Cooney,et al.  Early onset prostate cancer: predictors of clinical grade. , 2002, The Journal of urology.

[56]  L. Shaw,et al.  Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers. , 1986, Urology.

[57]  T. Y. Wang,et al.  Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer. , 1986, Annals of clinical and laboratory science.

[58]  Michael W Kattan,et al.  Nomograms as predictive models. , 2002, Seminars in urologic oncology.

[59]  M. Riggs,et al.  Stage at presentation and survival of white and black patients with prostate carcinoma , 1993, Cancer.

[60]  E. Rimm,et al.  Body mass index and risk of prostate cancer in U.S. health professionals. , 2003, Journal of the National Cancer Institute.

[61]  N. George.  NATURAL HISTORY OF LOCALISED PROSTATIC CANCER MANAGED BY CONSERVATIVE THERAPY ALONE , 1988, The Lancet.

[62]  Marc Shapiro,et al.  Prostate cancer in black and white Americans , 2003, Cancer and Metastasis Reviews.

[63]  N. Makridakis,et al.  Molecular epidemiology of androgen-metabolic loci in prostate cancer: predisposition and progression. , 2004, The Journal of urology.

[64]  P. Guinan,et al.  An evaluation of prostate specific antigen in prostatic cancer. , 1987, The Journal of urology.

[65]  S. Loening,et al.  A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. , 2003, The Journal of urology.

[66]  M. Hara,et al.  [Some physico-chemical characteristics of " -seminoprotein", an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII]. , 1971, Nihon hoigaku zasshi = The Japanese journal of legal medicine.

[67]  I. Bairati,et al.  Dietary fat and prostate cancer survival , 1999, Cancer Causes & Control.

[68]  W. Cooner,et al.  Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. , 1990, The Journal of urology.

[69]  E. Deantoni,et al.  Eight years of "Prostate cancer awareness week" , 1997, Cancer.

[70]  R. Lamerz,et al.  Screening for prostatic carcinoma with prostate specific antigen. , 1997, Anticancer research.

[71]  J. Moul,et al.  Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. , 1998, Urology.

[72]  E. Metter,et al.  Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. , 1995, Urology.

[73]  R. Vessella,et al.  Screening for prostatic carcinoma with prostate specific antigen: results of the second year. , 1993, The Journal of urology.

[74]  J. Moul,et al.  Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. , 2001, Urology.

[75]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[76]  B A Miller,et al.  The role of increasing detection in the rising incidence of prostate cancer. , 1995, JAMA.

[77]  W. A. Soanes,et al.  Precipitating antigens of the normal human prostate. , 1970, Journal of reproduction and fertility.

[78]  W. Catalona,et al.  Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. , 1994, The Journal of urology.

[79]  A W Partin,et al.  Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. , 1996, Urology.

[80]  C G Chute,et al.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.

[81]  J. Eastham,et al.  Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. , 1998, Journal of the National Cancer Institute.

[82]  J. Manola,et al.  Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[83]  N. George.  NATURAL HISTORY OF LOCALISED PROSTATIC CANCER MANAGED BY CONSERVATIVE THERAPY ALONE , 1988, The Lancet.

[84]  I. Thompson,et al.  Association of African-American ethnic background with survival in men with metastatic prostate cancer. , 2001, Journal of the National Cancer Institute.

[85]  G. Murphy,et al.  Purification of a human prostate specific antigen. , 1979, Investigative urology.

[86]  J. Adolfsson,et al.  Deferred treatment of locally advanced nonmetastatic prostate cancer: a long-term followup. , 1999, The Journal of urology.

[87]  H. Klocker,et al.  Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. , 2003, The Journal of urology.

[88]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.

[89]  P. Ruff,et al.  Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. , 1997, American journal of clinical oncology.

[90]  P. Walsh.  Results of conservative management of clinically localized prostate cancer. , 1994, The Journal of urology.

[91]  J. Lynch,et al.  Daily variability in human serum prostate-specific antigen and prostatic acid phosphatase: a comparative evaluation. , 1988, Urology.

[92]  A. McCall,et al.  Factors that influence biochemical failure after radiation therapy for stage T1c prostate cancer. , 1998, American journal of clinical oncology.

[93]  P. Littrup,et al.  The use of transrectal ultrasound in the diagnosis, guided biopsy, staging and screening of prostate cancer. , 1987, Radiographics : a review publication of the Radiological Society of North America, Inc.

[94]  F. Mostofi,et al.  Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. , 1995, JAMA.

[95]  Timothy F. Donahue,et al.  Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  L A Kalish,et al.  Family history and the risk of prostate cancer. , 2000, Urology.

[97]  R. Kittles,et al.  Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[98]  Srinivasan Vijayakumar,et al.  Racial differences in prostate-specific antigen levels and prostate-specific antigen densities in patients with prostate cancer. , 1999, American journal of clinical oncology.

[99]  T. Stamey,et al.  Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. , 2002, Urology.

[100]  I. Thompson,et al.  Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. , 2002, The Journal of urology.

[101]  J. Richie,et al.  Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. , 1994, The Journal of urology.

[102]  W. Catalona,et al.  The nature of prostate cancer detected through prostate specific antigen based screening. , 1994, The Journal of urology.

[103]  J. Oesterling,et al.  Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. , 1988, The Journal of urology.

[104]  J. Moul,et al.  Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. , 2000, The Journal of urology.

[105]  M. Terris,et al.  Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  L. Holmberg,et al.  Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. , 1997, JAMA.

[107]  Louis R Kavoussi,et al.  Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. , 1994, The Journal of urology.

[108]  W. Catalona,et al.  Effect of ejaculation on serum total and free prostate-specific antigen concentrations. , 1997, Urology.

[109]  P. Walsh.  The definition and preoperative prediction of clinically insignificant prostate cancer. , 1996, The Journal of urology.

[110]  M. Barry,et al.  Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. , 1996, Journal of the National Cancer Institute.

[111]  M. Blute,et al.  Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance? , 2004, Urologic oncology.

[112]  M. Terris,et al.  Utilization of polyclonal serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values. , 1994, British journal of urology.

[113]  D. Ornstein,et al.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. , 1997, JAMA.

[114]  M. Pike,et al.  Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA , 1999, The Lancet.

[115]  K. Shinohara,et al.  The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. , 2000, The Journal of urology.

[116]  P. Engstrom,et al.  Relative risk of prostate cancer for men with affected relatives: Systematic review and meta‐analysis , 2003, International journal of cancer.

[117]  D. Lubeck,et al.  Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy? , 2002, The Journal of urology.

[118]  I. Thompson,et al.  Ten-year survival in patients with metastatic prostate cancer. , 2003, Clinical prostate cancer.

[119]  H. Ragde,et al.  Ultrasound-guided prostate biopsy. Biopty gun superior to aspiration. , 1988, Urology.

[120]  R A Stephenson,et al.  Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. , 2001, Journal of the National Cancer Institute.

[121]  S. Coughlin,et al.  A review of genetic polymorphisms and prostate cancer risk. , 2002, Annals of epidemiology.

[122]  H. Fuse,et al.  Metastatic prostate cancer with normal level of serum prostate-specific antigen , 2004, International Urology and Nephrology.

[123]  Assessment of outcome prediction models for localized prostate cancer in patients managed with external beam radiation therapy. , 1998, Seminars in urologic oncology.

[124]  J. Oesterling,et al.  Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. , 1996, Urology.